View in EDS HTML Full Text PDF Full Text

Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis: A Double-blind, Vehicle-Controlled Phase 2a Randomized Clinical Trial.

Saved in:
Bibliographic Details
Title: Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis: A Double-blind, Vehicle-Controlled Phase 2a Randomized Clinical Trial.
Authors: Zirwas MJ; Dermatologists of the Central States, Bexley, Ohio.; Probity Medical Research, Bexley, Ohio.; Ohio University, Bexley., Draelos ZD; Dermatology Consulting Services, High Point, North Carolina., DuBois J; DermResearch, Inc, Austin, Texas., Kircik LH; Icahn School of Medicine at Mount Sinai, New York, New York.; Physicians Skin Care, PLLC, Louisville, Kentucky.; Indiana Medical Center, Indianapolis.; Skin Sciences, PLLC, Louisville, Kentucky., Moore AY; Arlington Center for Dermatology, Arlington Research Center, Arlington, Texas.; Baylor University Medical Center, Dallas, Texas., Stein Gold L; Henry Ford Medical Center, Detroit, Michigan., Alonso-Llamazares J; Driven Research LLC, Coral Gables, Florida., Bukhalo M; Arlington Dermatology, Rolling Meadows, Illinois., Bruce S; SBA Dermatology, Houston, Texas., Eads K; The Indiana Clinical Trials Center, PC, Plainfield., Green LJ; George Washington University School of Medicine, Rockville, Maryland., Guenthner ST; The Dermatology Center of Indiana, PC, Plainfield.; The Indiana Clinical Trials Center, PC, Plainfield., Ferris LK; University of Pittsburgh, Department of Dermatology, Pittsburgh, Pennsylvania., Forman SB; ForCare Medical Center, Tampa, Florida., Kempers SE; Minnesota Clinical Study Center, Fridley., Lain E; Sanova Dermatology, Austin, Texas., Lynde CW; University of Toronto, Toronto, Ontario, Canada.; Lynde Centre for Dermatology, Markham, Ontario, Canada.; Probity Medical Research, Markham, Ontario, Canada., Pariser DM; Eastern Virginia Medical School, Norfolk.; Virginia Clinical Research, Inc, Norfolk., Toth DP; XLR8 Medical Research, Windsor, Ontario, Canada.; Probity Medical Research, Windsor, Ontario, Canada., Yamauchi PS; David Geffen School of Medicine at UCLA, Los Angeles, California.; Dermatology Institute & Skin Care Center, Inc, Santa Monica, California., Higham RC; Arcutis Biotherapeutics, Inc, Westlake Village, California., Krupa D; Arcutis Biotherapeutics, Inc, Westlake Village, California., Burnett P; Arcutis Biotherapeutics, Inc, Westlake Village, California., Berk DR; Arcutis Biotherapeutics, Inc, Westlake Village, California.
Source: JAMA dermatology [JAMA Dermatol] 2023 Jun 01; Vol. 159 (6), pp. 613-620.
Publication Type: Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Medical Association Country of Publication: United States NLM ID: 101589530 Publication Model: Print Cited Medium: Internet ISSN: 2168-6084 (Electronic) Linking ISSN: 21686068 NLM ISO Abbreviation: JAMA Dermatol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:2168-6084
DOI:10.1001/jamadermatol.2023.0846